Grob, J., Amonkar, M. M., Martin-Algarra, S., Demidov, L. V., Goodman, V., Grotzinger, K., . . . Hauschild, A. (2016). Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: Quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU).
Chicago-Zitierstil (17. Ausg.)Grob, J.-J, et al. Patient Perception of the Benefit of a BRAF Inhibitor in Metastatic Melanoma: Quality-of-life Analyses of the BREAK-3 Study Comparing Dabrafenib with Dacarbazine. Erlangen: Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2016.
MLA-Zitierstil (9. Ausg.)Grob, J.-J, et al. Patient Perception of the Benefit of a BRAF Inhibitor in Metastatic Melanoma: Quality-of-life Analyses of the BREAK-3 Study Comparing Dabrafenib with Dacarbazine. Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2016.